search
Back to results

The Effect of Carboxymetyl Starch (Oozfix) on Preventing Postoperative Complication After Gastrectomy (OOZFIX)

Primary Purpose

Stomach Neoplasm

Status
Recruiting
Phase
Phase 4
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Oozfix
Greenplast
Sponsored by
Bucheon St. Mary's Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Stomach Neoplasm

Eligibility Criteria

19 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Gastric adenocarcinoma patient who underwent radical gastrectomy at Bucheon St. Mary's Hospital Patient's Age is above 19 and less than 80 ECOG performance score : 0~2 Exclusion Criteria: Patient who underwent emergent gastrectomy Patient who requires palliative gastrectomy due to advanced or metastatic carcinoma Patient who requires operation due to other malignancy other than adenocrcinoma Patient who underwent emergent gastrectomy or pancreatectomy before this study Patient who underwent chemoradiation Patient who took anticoagulants or with coagulopathy

Sites / Locations

  • BucheonStMarysRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Oozfix

Greenplast

Arm Description

Arm with oozfix after gastrectomy

Arm with greenplast after gastrectomy

Outcomes

Primary Outcome Measures

Ratio of (patient who suffers from) pancreatic fistula
Ratio of patient who suffers from pancreatic fistula

Secondary Outcome Measures

Full Information

First Posted
November 15, 2022
Last Updated
December 8, 2022
Sponsor
Bucheon St. Mary's Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05645198
Brief Title
The Effect of Carboxymetyl Starch (Oozfix) on Preventing Postoperative Complication After Gastrectomy
Acronym
OOZFIX
Official Title
The Effect of Carboxymetyl Starch (Oozfix) on Preventing Postoperative Complication After Gastrectomy: Single-center, Non-inferiority, Open-label Randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
October 26, 2022 (Actual)
Primary Completion Date
December 31, 2024 (Anticipated)
Study Completion Date
January 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Bucheon St. Mary's Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Although the technique of radical gastrectomy had been advanced, postoperative complication can occur in 13~25% of patient after radical gastrectomy. Pancreatic fistula and postoperative bleeding was reported as 2~30% and 1~2%, respectively. These complications often result fatal clinical course, so localized fibrin agent has been widely used at postoperative surgical bed after radical gastrectomy. Recently, natural origin polysaccharide-based carboxymetyl starch was approved as localized coagulative, no well-designed report was adressed in gastric cancer surgery field. This agent can formate physical barrier after application, thus can prevent microbleeding or pancreatic fistula after gastrectomy. THIS study is single-center, non-inferiority, open-label randomized trial that evaluates the effect of carboxymetyl starch (Oozfix) on preventing postoperative complication after gastrectomy.
Detailed Description
Although the technique of radical gastrectomy had been advanced, postoperative complication can occur in 13~25% of patient after radical gastrectomy. Pancreatic fistula and postoperative bleeding was reported as 2~30% and 1~2%, respectively. These complications often result fatal clinical course, so localized fibrin agent has been widely used at postoperative surgical bed after radical gastrectomy. Recently, natural origin polysaccharide-based carboxymetyl starch was approved as localized coagulative, no well-designed report was adressed in gastric cancer surgery field. This agent can formate physical barrier after application, thus can prevent microbleeding or pancreatic fistula after gastrectomy. THIS study is single-center, non-inferiority, open-label randomized trial that evaluates the effect of carboxymetyl starch (Oozfix) on preventing postoperative complication after gastrectomy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stomach Neoplasm

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
180 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Oozfix
Arm Type
Experimental
Arm Description
Arm with oozfix after gastrectomy
Arm Title
Greenplast
Arm Type
Active Comparator
Arm Description
Arm with greenplast after gastrectomy
Intervention Type
Drug
Intervention Name(s)
Oozfix
Other Intervention Name(s)
Case group
Intervention Description
Directly apply carboxymetyl starch (Oozfix) 5 gram evenly at the suprapancreatic surgical bed after gastrectomy
Intervention Type
Drug
Intervention Name(s)
Greenplast
Other Intervention Name(s)
Control Group
Intervention Description
Directly apply Greenplast (Aprotinin 1000kIU/mL, Thrombin 500IU/mL, Fibrinogen 95mg/mL) 4 gram evenly at the suprapancreatic surgical bed after gastrectomy
Primary Outcome Measure Information:
Title
Ratio of (patient who suffers from) pancreatic fistula
Description
Ratio of patient who suffers from pancreatic fistula
Time Frame
Postoperative day 3

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Gastric adenocarcinoma patient who underwent radical gastrectomy at Bucheon St. Mary's Hospital Patient's Age is above 19 and less than 80 ECOG performance score : 0~2 Exclusion Criteria: Patient who underwent emergent gastrectomy Patient who requires palliative gastrectomy due to advanced or metastatic carcinoma Patient who requires operation due to other malignancy other than adenocrcinoma Patient who underwent emergent gastrectomy or pancreatectomy before this study Patient who underwent chemoradiation Patient who took anticoagulants or with coagulopathy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hayemin LEE
Phone
+82+032-340-7631
Email
hymin@catholic.ac.kr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hayemin LEE
Organizational Affiliation
Bucheon St. Mary's Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
BucheonStMarys
City
Bucheon-Si
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hayemin Lee

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33319151
Citation
Washio M, Yamashita K, Niihara M, Hosoda K, Hiki N. Postoperative pancreatic fistula after gastrectomy for gastric cancer. Ann Gastroenterol Surg. 2020 Sep 21;4(6):618-627. doi: 10.1002/ags3.12398. eCollection 2020 Nov.
Results Reference
background

Learn more about this trial

The Effect of Carboxymetyl Starch (Oozfix) on Preventing Postoperative Complication After Gastrectomy

We'll reach out to this number within 24 hrs